

Pharmaceutical Industry China Q2 2013 - An In Depth Analysis of Multinational and Chinese Biopharma Companies, Industry Trends, Environment, Regulation, Market Drivers, Restraints, Opportunities & Challenges

<https://marketpublishers.com/r/PA28D42A1EAEN.html>

Date: July 2013

Pages: 142

Price: US\$ 3,400.00 (Single User License)

ID: PA28D42A1EAEN

Abstracts

“Pharmaceutical Industry China Q2 2013 – Cutting-Edge Analysis of Multinational and Chinese Biopharma Companies, Industry Trends, Environment, Regulation, Market Drivers, Restraints, Opportunities & Challenges” provides you with a detailed investigation of the market size, segmentation, key players, SWOT analysis, influential Government policies, and business and economic environments. The report is supported by over 196 tables & figures within 135 pages. The Chinese biopharmaceutical market is presented as follows:

By Company (e.g., AMOYTOP BIOTECH, BEIJING CONTINENT PHARMACEUTICALS, FUSOGEN, SHANGHAI HUAGUAN BIOCHIP, SIBIONO GENETECH, ABBOTT, ROCHE, PFIZER, GSK, NOVARTIS)

By Therapeutic Area (e.g., Anti-infective, Cancer, Diabetes, Dementia, Depression)

A wealth of financial information is provided including:

Company financials, sales & revenue figures – historical to Q2 2013

China GDP, economic growth, export (bulk drug, formulations) figures

Indian health expenditure as a function of GDP

Growth change figures of emerging and developing countries (India, Russia, China, Brazil)

Economic growth figures of advanced economies (USA, UK, Germany, France, Italy, Spain, Japan, Canada)

Projected figures of strategic emerging industry GDP percentage contribution

SWOT, Economic and Business Environment specifics include:

Key strengths, weaknesses and threats influencing leading player position within the market

Top Five Contract Pharmaceutical Export Markets of China

Major players within China's leading therapeutic markets (e.g., cancer, allergy, liver disease)

Multinational penetration into the Chinese Pharma Market

Comprehensive product portfolios, R&D activity and pipeline therapeutics

M&A activity and future strategies of top Chinese pharmacos

Economic indicators, trade policy, merchandise and commercial trade statistics

Gross Domestic Product of China, historic and projection analysis

Chinese economic outlook in comparison to advanced economies

Three Tier 'Pharmerging' Markets with Potential for Significant Growth

Prescription drug sales distribution channels in China

Major biogeneric products in China

This report highlights a number of significant Chinese and multinational pharmacos and gives details of their operations, products, financials and business strategy.

Amoytop Biotech

Active Pharmaceutical Products

Beijing Continent Pharmaceuticals

FusoGen Pharmaceuticals

Shanghai Huaguan Biochip

SiBiono GeneTech

Abbott

AstraZeneca

Boehringer Ingelheim

Eli Lilly

GlaxoSmithKline

Johnson & Johnson Medical

Merck

Novartis

Pfizer

Roche

Forecast projections and future growth rates are provided to give you a forthcoming perspective of this growing industry. Current developments relating to patent expirations, government funding, and regulations are discussed. The emerging trends

that appear in key sub-markets such as generics, oncology, cardiovascular, diabetes and vaccines are elucidated and analysed.

What you will gain:

An in-depth understanding of the Chinese biopharmaceutical market and it's environment

Current market facts, figures and product lines of key players in the industry

An insight into how generic therapeutics will propagate the Chinese biopharmaceutical market

Knowledge of how the Chinese pharma market will integrate into the global healthcare market

Information on key regulatory and government policies

Data on levels of private and publically funded biopharma studies in China

Strategies on how to adapt and restructure current business models to this industry

This report tackles key concerns to the Chinese biopharmaceutical market such as:

Lack of regulatory policy and legislation

Reimbursement schemes and payers concerns

Funding and government sponsorship issues

International scepticism of Chinese safety and efficacy therapeutic profiles

This report will tell you if the companies mentioned are:

Strong, competitive players

Pooling their resources for specific growth and therapeutic areas

Investing strategically in R&D

Have a history of strategic M&A activity

Contents

1.0 SUMMARY

- 1.1 Objectives of Report
- 1.2 Scope of Study
- 1.3 Data Sources and Methodology
- 1.4 Key Findings and Observations
- 1.5 Executive Summary

2.0 CHRONIC DISEASE PREVALENCE STATISTICS

3.0 BUSINESS ENVIRONMENT

- 3.1 Economic Indicators, Trade Policy and Merchandise and Commercial Trade Statistics
- 3.2 Gross Domestic Product of China, Historic and Projection Analysis
- 3.3 Annual Health Expenditure in China, Historic and Projected Analysis
- 3.4 Global and Chinese Economic Outlook 2010-2013
- 3.5 Chinese Economic Outlook in Comparison to Emerging Markets and Developing Countries
- 3.6 Chinese Economic Outlook in Comparison to Advanced Economies (US, Europe)

4.0 CHINESE PHARMACEUTICAL MARKET

- 4.1 Market Overview
- 4.2 Main Players in China's Pharmaceutical Industry
- 4.3 Anti-Allergy Drug Market
- 4.4 Asthma Drug Market
- 4.5 Benign Prostate Hyperplasia Drug Market
- 4.6 Anti-Depressant Drug market
- 4.7 Dermatitis Drug Market
- 4.8 Diabetes Drug Market
- 4.9 Hypertension Drug Market
- 4.10 Dyslipidaemia Drug Market
- 4.11 Senile Dementia Drug Market
- 4.12 Cancer Drug Market
- 4.13 Rheumatoid Arthritis Drug Market
- 4.14 Ophthalmological Drug Market

4.15 Liver Disease Drug Market

4.16 Antibiotic Drug Market

5.0 GOVERNMENT AND REGULATION ENVIRONMENT

5.1 12th Five Year Plan

5.2 Intellectual Property for Pharmaceuticals in China

5.3 State Food and Drug Administration (SFDA)

5.4 Pharmaceutical Distribution Process in China

6.0 CHINA – THIRD LARGEST PHARMA MARKET 2012

6.1 China – At the Forefront of Emerging Markets

6.2 Generic Medication Market and China

6.3 Novel Product Drug Development

6.4 Drug Development Cost and Outsourcing

6.5 Drug Development Case Study - Beijing Continent Pharmaceuticals

6.6 China's Pharmaceutical Export Market

6.7 Spot Light - China Medical City Taizhou

7.0 GLOBAL PHARMACEUTICAL COMPANIES INTEREST IN CHINA

7.1 Abbott China

7.2 AstraZeneca China

7.3 Bayer China

7.4 Boehringer Ingelheim China

7.5 Eli Lilly China

7.6 GlaxoSmithKline China

7.7 Johnson & Johnson Medical China

7.8 Merck China

7.9 Novartis China

7.10 Novo Nordisk China

7.11 Pfizer China

7.11.1 Pfizer China R&D Centre

7.11.2 Pfizer China Products

7.12 Roche China

7.13 Sanofi China

8.0 CHINESE PHARMACEUTICAL COMPANIES

- 8.1 Amoytop Biotech
- 8.2 Active Pharmaceutical Products
 - 8.2.1 Research and Development
 - 8.2.2 Financial Information
- 8.3 Beijing Continent Pharmaceuticals
- 8.4 FusoGen Pharmaceuticals
 - 8.4.1 Financial Information
- 8.5 Shanghai Huaguan Biochip
 - 8.5.1 Financial Information
- 8.6 SiBiono GeneTech
 - 8.6.1 Financial Information
- 8.7 Sinovac Biotech
 - 8.7.1 Financial Information
 - 8.7.2 New Products
 - 8.7.3 Split Virion Pandemic Influenza Vaccine
 - 8.7.4 RabEnd
 - 8.7.5 Pipeline Portfolio
 - 8.7.6 EV71 virus Vaccine
 - 8.7.7 Pneumococcal Conjugate Vaccine
 - 8.7.8 Pneumococcal Polysaccharide Vaccine
 - 8.7.9 Varicella Vaccine
 - 8.7.10 Measles, Mumps and Rubella Vaccines
 - 8.7.11 Rotavirus Vaccine

9.0 DRIVERS, RESTRAINTS, CHALLENGES AND OPPORTUNITY ANALYSIS

- 9.1 Key Drivers of the Pharmaceutical Market in China
- 9.2 Key Restraints of the Pharmaceutical Market in China
- 9.3 Challenges of the Pharmaceutical Industry in China
- 9.4 Opportunities Within BioPharma China

List Of Tables

LIST OF TABLES

Table 2.1: Most Prominent Cancer Manifestations in China

Table 2.2: Top Fifty Diseases in China Today (non-cancer)

Table 2.3: Top Infectious Disease States in China Today

Table 3.1: World Trade Organisation Basic Indicators on China

Table 3.2: World Trade Organisation Trade Policy of China

Table 3.3: World Trade Organisation Merchandise Trade Statistics: China

Table 3.4: World Trade Organisation Commercial Services Trade Statistics: China

Table 3.5: Summary of International Monetary Fund Members' Quota, Reserve Position, SDR Holdings, Outstanding Credit, Recent Lending Arrangements, Projected Payments Due and Monthly Historical Transactions of China

Table 3.6: China Statistics

Table 4.1: Top Global Pharma Markets 2003-2013

Table 4.2: Major Players in China's Anti-Allergy Drug Market

Table 4.3: Major Players in China's Asthma Drug Market

Table 4.4: Major Players in China's Benign Prostate Hyperplasia (BPH) Drug Market

Table 4.5: Major Players in China's Anti-Depressant Drug Market

Table 4.6: Prescription Dermatitis Drug Industry Sub-Markets and Associated Therapeutics

Table 4.7: Top Prescription Dermatitis Drugs on the Chinese Market

Table 4.8: Major Players in China's Dermatitis Drug Market

Table 4.9: Major Players in China's Diabetic Drug Market

Table 4.10: Major Players in China's Hypertension Drug Market

Table 4.11: Major Players in China's Dyslipidaemia Drug Market

Table 4.12: Major Players in China's Senile Dementia Drug Market

Table 4.13: Major Players in China's Cancer Drug Market

Table 4.14: Major Players in China's Rheumatoid Arthritis Drug Market

Table 4.15: Major Players in China's Ophthalmological Drug Market

Table 4.16: Major Players in China's Liver Disease Drug Market

Table 4.17: Major Players in China's Antibiotic Drug Market

Table 5.1: Seven Strategic Emerging Industries of China's 12th Five Year Plan 2011-2015

Table 5.2: Outline of the Chinese Promotion Plan for the Implementation of the National Intellectual Property Strategy, 2012

Table 5.3: Challenges facing the Pharmaceutical Distribution Business in China

Table 5.4: Prescription Drug Sales Distribution Channels in China

Table 6.1: Major Biogeneric Products in China
Table 6.2: Imported Therapeutics with Administrative Protection in China
Table 6.3: Expired Proprietary Pharmaceuticals in China
Table 6.4: Reasons Why Multinational Companies Seek CMO's in China
Table 6.5: Comparison of Clinical Trial Cost between China and the USA
Table 6.6: Five Functional Districts of China Medical City
Table 6.7: Five Key R&D and Manufacturing Areas within China Medical City
Table 7.1: Top Multinational Company Performance, China
Table 7.2: Abbott Areas of Expertise
Table 7.3: Abbott Key Global Products
Table 7.4: AbbVie (Abbott) Speciality Care Products Holding Market-Leading Positions
Table 7.5: Abbott China Anaesthesia Product Profile
Table 7.6: Abbott China Cardiovascular Product Profile
Table 7.7: Abbott China Vaccine Product Profile
Table 7.8: Abbott China Digestion Product Profile
Table 7.9: Abbott China HIV Product Profile
Table 7.10: Abbott Rheumatology HIV Product Profile
Table 7.11 Abbott China Gynaecological Product Profile
Table 7.12 Abbott China Urological Product Profile
Table 7.13 Abbott China Liver Disease Product Profile
Table 7.14 Abbott China Diagnostic Product Profile
Table 7.15: Abbott China Molecular Diagnostic Product Profile
Table 7.16: Abbott Blood Glucose Meter Product Profile
Table 7.17: Abbott Cardiovascular Product Profile
Table 7.18: Abbott Rapid Bedside Diagnostic/ Point of Care Product Profile
Table 7.19: Important Milestones in AstraZeneca China's History
Table 7.20: AstraZeneca China Anaesthetic Range of Products
Table 7.21: AstraZeneca China Cardiovascular and Metabolism Range of Products
Table 7.22: AstraZeneca China Gastrointestinal Range of Products
Table 7.23: AstraZeneca China Infection Range of Products
Table 7.24: AstraZeneca China Neurology Range of Products
Table 7.25: AstraZeneca China Oncology Range of Products
Table 7.26: AstraZeneca China Respiratory Range of Products
Table 7.27: AstraZeneca Top Branded Pharmaceuticals Globally 2012
Table 7.28: AstraZeneca Sales (US\$ Mil) of Top Branded Pharmaceuticals Globally 2010-2012
Table 7.29: Bayer China Important Milestones
Table 7.30: Therapeutic Areas Covered by Bayer Healthcare Pharmaceuticals in China
Table 7.31: Bayer - Leading Therapeutics in China

Table 7.32: Bayer Top Selling Consumer Health Products
Table 7.33: Boehringer Ingelheim Major Products in China
Table 7.34: Main Therapeutic Areas of Interest to Boehringer Ingelheim China
Table 7.35: Global Therapeutic Pipeline, Boehringer Ingelheim
Table 7.36: Major Global Boehringer Ingelheim Therapeutic Products
Table 7.37: GlaxoSmithKline Prescription Portfolio and Indications in China
Table 7.38: GlaxoSmithKline Vaccine Portfolio and Indications in China
Table 7.39: GlaxoSmithKline Over the Counter Portfolio and Indications in China
Table 7.40: GlaxoSmithKline Global Pharmaceutical Sales by Therapeutic Area, 2012
Table 7.41: GlaxoSmithKline Global Vaccine Sales 2012
Table 7.42: Significant Milestones in Johnson and Johnson China History
Table 7.43: Johnson & Johnson Pharmaceutical Segment Sales (US\$ Billion) by Therapeutic Area and Percentage Change, 2012
Table 7.44: Merck Serono Pharmaceutical Key Therapeutic Areas in China
Table 7.45: Merck Serono Fertility and Infertility Therapeutic Portfolio in China
Table 7.46: Merck Serono Therapeutic Portfolio in China
Table 7.47: Merck Pharmaceutical Hong Kong Therapeutic Portfolio
Table 7.48: Range of Diabetic Products from Novo Nordisk China
Table 7.49: QUICKFACTs - Pfizer China
Table 7.50: Important Milestones – Pfizer China
Table 7.51: Pfizer China – Range of Infectious Disease Therapeutics for Chinese Health Care Market
Table 7.52: Pfizer China – Range of Mental Health Products for Chinese Health Care Market
Table 7.53: Pfizer China – Range of Genitourinary Products for Chinese Health Care Market
Table 7.54: Pfizer China – Range of Endocrine Products for Chinese Health Care Market
Table 7.55: Pfizer China – Range of Women’s Health Products for Chinese Health Care Market
Table 7.56: Pfizer China – Range of Cardiovascular Disease Products for Chinese Health Care Market
Table 7.57: Pfizer China – Range of Oncology Products for Chinese Health Care Market
Table 7.58: Pfizer – Key Consumer Healthcare Global Products
Table 7.59: Pfizer – Key Speciality Care Global Products
Table 7.60: Pfizer – Key Oncology Global Products
Table 7.61: Pfizer – Key Global Established Products
Table 7.62: Pfizer – Key Innovative Products in Emerging Markets
Table 7.63: Pfizer – Key Animal Health Global Products

Table 7.64: Pfizer Product Sales with Significant Impact on Revenues 2011:2012 Comparison

Table 7.65: Roche Pharmaceuticals Product List in China

Table 7.66: Roche Global Sales (CHF Millions) by Therapeutic Area, 2011, 2012 and Percentage Change (CER)

Table 7.67: Roche Pharmaceutical Division Sales from Brazil, China, India, Mexico, Russia, South Korea, Turkey, 2011, 2012 and Percentage Change (CER)

Table 7.68: Seven Growth Platforms of Sanofi China

Table 7.69: Key Therapeutic Areas of Sanofi China

Table 8.1: Important Milestones in Amoytop Biotech's Development

Table 8.2: Amoytop Biotech – Main Objectives of Research and Development Division

Table 8.3: Amoytop Biotech – Panel of Recombinant Protein Therapeutics in Clinical Studies

Table 8.4: Amoytop Biotech Portfolio of Patented Y-Shaped Branched Pegylated Recombinant Protein Therapeutics within Clinical Investigation in China

Table 8.5: Current Recombinant protein therapeutics by Amoytop Biotech

Table 8.6: Active Pharmaceutical Product Portfolio of Amoytop Biotech

Table 8.7: Milestones Achieved by FusoGen Pharmaceuticals

Table 8.8: Research and Development Sub-groups of FusoGen Pharmaceuticals

Table 8.9: Shanghai Huaguan Biochip Rapid Test Portfolio

Table 8.10: Shanghai Huaguan Biochip Multi Drugs of Abuse Test Profile

Table 8.11: Shanghai Huaguan Biochip Infectious Disease Test Portfolio

Table 8.12: Shanghai Huaguan Biochip Diagnostic Test Portfolio

Table 8.13: Shanghai Huaguan Biochip Laboratory Service Portfolio

Table 8.14: Intracellular Functions of the Gene Therapy Agent, Gendicine by SiBiono GeneTech

Table 8.15: Gendicine - Potential Oncology Indications for Future Approval

Table 8.16: Current Human Vaccine Portfolio of Sinovac Biotech

Table 8.17: Important Milestones in the History of Sinovac Biotech

Table 8.18: Pipeline Portfolio of Sinovac Biotech

Table 8.19: Total Sales Figures Sinovac Biotech 2007-2012

Table 9.1: Key Drivers of the Pharmaceutical Market in China

Table 9.2: Key Restraints of the Pharmaceutical Market in China

Table 9.3: Key Challenges of the Pharmaceutical Market in China

Table 9.4: Patent Expirations of Selected Top Brand Name Therapeutics by 2020

Table 9.5: Leading Pharmaceutical Areas with Significant Opportunities in China

About

Chronic Disease in China

One fifth of the total Chinese population – 260 million people suffer from chronic disease and according to the World Health Organization 79% of all deaths are due to chronic disease. The main chronic disease states in China are as follows:

Diabetes

Respiratory illness

Cancer

Cardiovascular disease

Cerebrovascular disease

Given that almost half of the total Chinese population are at risk of developing a chronic disease, a three year 'Chronic diseases prevention and control work plan' was implemented in 2012 to help combat this health issue. Economically, chronic disease costs China billions. The World Health Organization estimated that between 2005-2015 diabetes, cardiovascular disease and stroke will cost the country \$558 billion.

Within the next decade, the WHO predicts that 80 million people will die from chronic disease in China. Disease states that are thought to increase include infectious disease, maternal and perinatal conditions and diabetes. Chronic disease deaths will increase by almost 20%, and diabetic deaths will increase by a predicted 50%. One of the key factors in chronic disease death is obesity and this is predicted to increase to 57% of men and 46% of women by 2015.

Government and Regulation Environment 12th Five Year Plan

The Communist Party of China (CPC) approved the 12th Five Year Plan (12th FYP) for National Economic and Social Development in 2010 for the 2011-2015 period. One of the primary objectives of this economic plan is to promote a GDP growth rate of 7%. Within urban areas the 12th FYP wants to create 45 million jobs with an unemployment

level of less than 5%. R&D expenditure will account for 2.2% of total GDP. Innovation is a key player in the 12th FYP with an objective of 3.3 patents per 10,000 people.

This report details the current intellectual property regulations for Pharmaceuticals in China as specified by the State Food and Drug Administration (SFDA). It also examines the pharmaceutical distribution process in China and yields opinions as to how it may improve.

Global Pharmaceutical Companies Interest in China

The top multinational pharmaceutical companies with a presence in China are discussed in this report. Specific information relating to their operations in China are detailed as are current products on the market, future patent expirations and novel pipeline therapeutics. Financial analysis on the following companies is also presented.

Abbott

AstraZeneca

Boehringer Ingelheim

Eli Lilly

GlaxoSmithKline

Johnson & Johnson Medical

Merck

Novartis

Pfizer

Roche

This report also highlights a number of domestic biopharma companies and gives details of their operations, products, financials and business strategy. The following companies were chosen for analysis as they have specific advantages that we believe

will drive the pharmaceutical industry in China.

I would like to order

Product name: Pharmaceutical Industry China Q2 2013 - An In Depth Analysis of Multinational and Chinese Biopharma Companies, Industry Trends, Environment, Regulation, Market Drivers, Restraints, Opportunities & Challenges

Product link: <https://marketpublishers.com/r/PA28D42A1EAEN.html>

Price: US\$ 3,400.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/PA28D42A1EAEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970